✦ LIBER ✦

Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?

✍ Scribed by Allison, Janette ;Seino, Ken-ichiro ;Yagita, Hideo

Publisher: Springer
Year: 1998
Tongue: English
Weight: 864 KB
Volume: 19
Category: Article
ISSN: 0344-4325
DOI: 10.1007/bf00787228

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FAS(CD95) ligand expression by tumor cel

FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejection

✍ Nathalie Favre; Bernard Bonnotte; Nathalie Droin; Annie Fromentin; Eric Solary; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 201 KB 👁 1 views

According to the results of in vitro experiments, Fas(CD95) ligand expression by cancer cells might induce apoptosis of activated T cells and contribute to immune tolerance. However, Fas ligand expression had never been explored in vivo in tumor cell models yielding either immune response or toleran

Roles of CXC chemokines and macrophages

Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor

✍ Motomu Shimizu; Takayuki Yoshimoto; Mayumi Sato; Junji Morimoto; Akio Matsuzawa; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 936 KB

## Abstract The role of CD95 ligand (FasL/Apo‐1L)‐expressing tumors in immunosuppression or immunopotentiation is controversial. CD95L‐transfected tumors induce immunopotentiation after vigorous neutrophil infiltration. Thus, the induction of neutrophil infiltration by CD95L seems to play an import